The controlled substances listed in this section are included in Schedule I and include any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, when the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation.
A. Any of the following opiates including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, when the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
1. Acetylmethadol;
2. Allylprodine;
3. Alphacetylmethadol;
4. Alphameprodine;
5. Alphamethadol;
6. Benzethidine;
7. Betacetylmethadol;
8. Betameprodine;
9. Betamethadol;
10. Betaprodine;
11. Clonitazene;
12. Dextromoramide;
13. Dextrorphan (except its methyl ether);
14. Diampromide;
15. Diethylthiambutene;
16. Dimenoxadol;
17. Dimepheptanol;
18. Dimethylthiambutene;
19. Dioxaphetyl butyrate;
20. Dipipanone;
21. Ethylmethylthiambutene;
22. Etonitazene;
23. Etoxeridine;
24. Furethidine;
25. Hydroxypethidine;
26. Ketobemidone;
27. Levomoramide;
28. Levophenacylmorphan;
29. Metonitazene;
30. Morpheridine;
31. Noracymethadol;
32. Norlevorphanol;
33. Normethadone;
34. Norpipanone;
35. Phenadoxone;
36. Phenampromide;
37. Phenomorphan;
38. Phenoperidine;
39. Piritramide;
40. Proheptazine;
41. Properidine;
42. Racemoramide; or
43. Trimeperidine.
B. Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
1. Acetorphine;
2. Acetyldihydrocodeine;
3. Benzylmorphine;
4. Codeine methylbromide;
5. Codeine-N-Oxide;
6. Cyprenorphine;
7. Desomorphine;
8. Dihydromorphine;
9. Etorphine;
10. Heroin;
11. Hydromorphinol;
12. Methyldesorphine;
13. Methylhydromorphine;
14. Morphine methylbromide;
15. Morphine methylsulfonate;
16. Morphine-N-Oxide;
17. Myrophine;
18. Nicocodeine;
19. Nicomorphine;
20. Normorphine;
21. Phoclodine;
22. Thebacon;
23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (Acetyl fentanyl);
24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide (Crotonyl fentanyl);
25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide (Furanyl fentanyl);
26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
27. N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (Butyrl fentanyl).
C. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
1. Methcathinone;
2. 3, 4-methylenedioxy amphetamine;
3. 3, 4-methylenedioxy methamphetamine;
4. 5-methoxy-3, 4-methylenedioxy amphetamine;
5. 3, 4, 5-trimethoxy amphetamine;
6. Bufotenine;
7. Diethyltryptamine;
8. Dimethyltryptamine;
9. 4-methyl-2, 5-dimethoxyamphetamine;
10. Ibogaine;
11. Lysergic acid diethylamide;
12. Marijuana;
13. Mescaline;
14. N-benzylpiperazine;
15. N-ethyl-3-piperidyl benzilate;
16. N-methyl-3-piperidyl benzilate;
17. Psilocybin;
18. Psilocyn;
19. 2, 5 dimethoxyamphetamine;
20. 4 Bromo-2, 5-dimethoxyamphetamine;
21. 4 methoxyamphetamine;
22. Cyclohexamine;
23. Salvia Divinorum;
24. Salvinorin A;
25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine; TPCP, TCP;
26. Phencyclidine (PCP);
27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
28. 1-(3-trifluoromethylphenyl) piperazine;
29. Flunitrazepam;
30. B-hydroxy-amphetamine;
31. B-ketoamphetamine;
32. 2,5-dimethoxy-4-nitroamphetamine;
33. 2,5-dimethoxy-4-bromophenethylamine;
34. 2,5-dimethoxy-4-chlorophenethylamine;
35. 2,5-dimethoxy-4-iodoamphetamine;
36. 2,5-dimethoxy-4-iodophenethylamine;
37. 2,5-dimethoxy-4-methylphenethylamine;
38. 2,5-dimethoxy-4-ethylphenethylamine;
39. 2,5-dimethoxy-4-fluorophenethylamine;
40. 2,5-dimethoxy-4-nitrophenethylamine;
41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
43. 2,5-dimethoxy-4-propylthio-phenethylamine;
44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
47. 5-methoxy-N, N-dimethyltryptamine;
48. N-methyltryptamine;
49. A-ethyltryptamine;
50. A-methyltryptamine;
51. N, N-diethyltryptamine;
52. N, N-diisopropyltryptamine;
53. N, N-dipropyltryptamine;
54. 5-methoxy-a-methyltryptamine;
55. 4-hydroxy-N, N-diethyltryptamine;
56. 4-hydroxy-N, N-diisopropyltryptamine;
57. 5-methoxy-N, N-diisopropyltryptamine;
58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
59. 3,4-Methylenedioxymethcathinone (Methylone);
60. 3,4-Methylenedioxypyrovalerone (MDPV);
61. 4-Methylmethcathinone (Mephedrone);
62. 4-methoxymethcathinone;
63. 4-Fluoromethcathinone;
64. 3-Fluoromethcathinone;
65. 1-(8-bromobenzo 1,2-b;4,5-b' difuran-4-yl)-2-aminopropane;
66. 2,5-Dimethoxy-4-chloroamphetamine;
67. 4-Methylethcathinone;
68. Pyrovalerone;
69. N,N-diallyl-5-methoxytryptamine;
70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
71. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
72. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
73. Alpha-Pyrrolidinopentiophenone;
74. 4-Fluoroamphetamine;
75. Pentedrone;
76. 4'-Methyl-a-pyrrolidinohexaphenone;
77. 2,5-dimethoxy-4-(n)-propylphenethylamine;
78. 2,5-dimethoxyphenethylamine;
79. 1,4-Dibenzylpiperazine;
80. N,N-Dimethylamphetamine;
81. 4-Fluoromethamphetamine;
82. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25C-NBOMe);
83. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe);
84. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine (25B-NBOMe);
85. 1-(4-Fluorophenyl)piperazine;
86. Methoxetamine;
87. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-methylbenzamide;
88. N-ethyl hexadrone;
89. Isopropyl-U-47700;
90. Para-fluorobutyrl fentanyl;
91. Fluoro isobutryrl fentanyl;
92. 3-Hydroxy Phencyclidine (PCP);
93. 3-methoxy Phencyclidine (PCP);
94. Flualprazolam; or
95. Flubromazolam.
D. Unless specifically excepted or unless listed in a different schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant or depressant effect on the central nervous system:
1. Fenethylline;
2. Mecloqualone;
3. N-ethylamphetamine;
4. Methaqualone;
5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium oxybate, and sodium oxybutyrate;
6. Gamma-Butyrolactone (GBL) as packaged, marketed, manufactured or promoted for human consumption, with the exception of legitimate food additive and manufacturing purposes;
7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or manufactured for human consumption, with the exception of legitimate food additive and manufacturing purposes;
8. Gamma Valerolactone (GVL) as packaged, marketed, or manufactured for human consumption, with the exception of legitimate food additive and manufacturing purposes;
9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, manufactured, or promoted for human consumption with the exception of legitimate manufacturing purposes; or
10. N-ethylpentylone.
E. 1. The following industrial uses of Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are excluded from all schedules of controlled substances under this title:
2. At the request of any person, the Director may exempt any other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol from being included as a Schedule I controlled substance if such product is labeled, marketed, manufactured and distributed for legitimate industrial use in a manner that reduces or eliminates the likelihood of abuse.
3. In making a determination regarding an industrial product, the Director, after notice and hearing, shall consider the following:
4. The hearing shall be held in accordance with the procedures of the Administrative Procedures Act.
F. Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
1. JWH-004;
2. JWH-007;
3. JWH-009;
4. JWH-015;
5. JWH-016;
6. JWH-018;
7. JWH-019;
8. JWH-020;
9. JWH-030;
10. JWH-046;
11. JWH-047;
12. JWH-048;
13. JWH-049;
14. JWH-050;
15. JWH-070;
16. JWH-071;
17. JWH-072;
18. JWH-073;
19. JWH-076;
20. JWH-079;
21. JWH-080;
22. JWH-081;
23. JWH-082;
24. JWH-094;
25. JWH-096;
26. JWH-098;
27. JWH-116;
28. JWH-120;
29. JWH-122;
30. JWH-145;
31. JWH-146;
32. JWH-147;
33. JWH-148;
34. JWH-149;
35. JWH-150;
36. JWH-156;
37. JWH-167;
38. JWH-175;
39. JWH-180;
40. JWH-181;
41. JWH-182;
42. JWH-184;
43. JWH-185;
44. JWH-189;
45. JWH-192;
46. JWH-193;
47. JWH-194;
48. JWH-195;
49. JWH-196;
50. JWH-197;
51. JWH-198;
52. JWH-199;
53. JWH-200;
54. JWH-201;
55. JWH-202;
56. JWH-203;
57. JWH-204;
58. JWH-205;
59. JWH-206;
60. JWH-207;
61. JWH-208;
62. JWH-209;
63. JWH-210;
64. JWH-211;
65. JWH-212;
66. JWH-213;
67. JWH-234;
68. JWH-235;
69. JWH-236;
70. JWH-237;
71. JWH-239;
72. JWH-240;
73. JWH-241;
74. JWH-242;
75. JWH-243;
76. JWH-244;
77. JWH-245;
78. JWH-246;
79. JWH-248;
80. JWH-249;
81. JWH-250;
82. JWH-251;
83. JWH-252;
84. JWH-253;
85. JWH-262;
86. JWH-292;
87. JWH-293;
88. JWH-302;
89. JWH-303;
90. JWH-304;
91. JWH-305;
92. JWH-306;
93. JWH-307;
94. JWH-308;
95. JWH-311;
96. JWH-312;
97. JWH-313;
98. JWH-314;
99. JWH-315;
100. JWH-316;
101. JWH-346;
102. JWH-348;
103. JWH-363;
104. JWH-364;
105. JWH-365;
106. JWH-367;
107. JWH-368;
108. JWH-369;
109. JWH-370;
110. JWH-371;
111. JWH-373;
112. JWH-386;
113. JWH-387;
114. JWH-392;
115. JWH-394;
116. JWH-395;
117. JWH-397;
118. JWH-398;
119. JWH-399;
120. JWH-400;
121. JWH-412;
122. JWH-413;
123. JWH-414;
124. JWH-415;
125. CP-55, 940;
126. CP-47, 497;
127. HU-210;
128. HU-211;
129. WIN-55, 212-2;
130. AM-2201;
131. AM-2233;
132. JWH-018 adamantyl-carboxamide;
133. AKB48;
134. JWH-122 N-(4-pentenyl)analog;
135. MAM2201;
136. URB597;
137. URB602;
138. URB754;
139. UR144;
140. XLR11;
141. A-796,260;
142. STS-135;
143. AB-FUBINACA;
144. AB-PINACA;
145. PB-22;
146. AKB48 N-5-Fluorpentyl;
147. AM1248;
148. FUB-PB-22;
149. ADB-FUBINACA;
150. BB-22;
151. 5-Fluoro PB-22; or
152. 5-Fluoro AKB-48.
G. In addition to those substances listed in subsection F of this section, unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following chemical groups:
1. Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthoylindoles include, but are not limited to:
2. Naphthylmethylindoles: any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthylmethylindoles include, but are not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);
3. Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole structure with or without substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the pyrrole ring to any extent, and whether or not substituted on the naphthyl group to any extent. Naphthoylpyrroles include, but are not limited to:
4. Naphthylideneindenes: any compound containing a 1-(1-naphthylmethylene)indene structure with or without substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indene group to any extent, and whether or not substituted on the naphthyl group to any extent. Naphthylmethylindenes include, but are not limited to, (1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176);
5. Phenylacetylindoles: any compound containing a 3-phenylacetylindole structure with or without substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl ring to any extent. Phenylacetylindoles include, but are not limited to:
6. Cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with or without substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, and whether or not further substituted on the cyclohexyl ring to any extent. Cyclohexylphenols include, but are not limited to:
7. Benzoylindoles: any compound containing a 3-(benzoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl group to any extent. Benzoylindoles include, but are not limited to:
8. Cyclopropoylindoles: Any compound containing a 3-(cyclopropoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the cyclopropoyl ring to any extent. Cyclopropoylindoles include, but are not limited to:
9. Indole Amides: Any compound containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole Amides include, but are not limited to:
10. Indole Esters: Any compound containing a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters include, but are not limited to:
11. Adamantanoylindoles: Any compound containing an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Adamantanoylindoles include, but are not limited to:
12. Carbazole Ketone: Any compound containing (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018);
13. Benzimidazole Ketone: Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include, but are not limited to:
14. Modified by Replacement: any compound defined in this subsection that is modified by replacement of a carbon with nitrogen in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
H. Any prescription drug approved by the federal Food and Drug Administration under the provisions of Section 505 of the Federal Food, Drug and Cosmetic Act, Title 21 of the United States Code, Section 355, that is designated, rescheduled or deleted as a controlled substance under federal law by the United States Drug Enforcement Administration shall be excluded from Schedule I and shall be prescribed, distributed, dispensed or used in accordance with federal law upon the issuance of a notice, final rule or interim final rule by the United States Drug Enforcement Administration designating, rescheduling or deleting as a controlled substance such a drug product under federal law, unless and until the Board of Pharmacy takes action pursuant to Section 2-201 of this title. If the Board of Pharmacy does not take action pursuant to Section 2-201 of this title, the drug product shall be deemed to be designated, rescheduled or deleted as a controlled substance in accordance with federal law and in compliance with the Uniform Controlled Dangerous Substances Act.
Added by Laws 1971, c. 119, § 2-204, operative Sept. 1, 1971. Amended by Laws 1976, c. 291, § 1, emerg. eff. June 17, 1976; Laws 1978, c. 194, § 3, emerg. eff. April 14, 1978; Laws 1984, c. 127, § 1, eff. Nov. 1, 1984; Laws 1987, c. 138, § 3, emerg. eff. June 19, 1987; Laws 1994, c. 140, § 1, eff. Sept. 1, 1994; Laws 1995, c. 54, § 2, eff. July 1, 1995; Laws 1998, c. 100, § 1, emerg. eff. April 13, 1998; Laws 2000, c. 16, § 1, emerg. eff. April 3, 2000; Laws 2001, c. 99, § 2, eff. July 1, 2001; Laws 2001, c. 373, § 2, eff. July 1, 2001; Laws 2005, c. 283, § 1, eff. Nov. 1, 2005; Laws 2008, c. 332, § 1, eff. Nov. 1, 2008; Laws 2010, c. 182, § 1, eff. Nov. 1, 2010; Laws 2011, c. 239, § 2, eff. Nov. 1, 2011; Laws 2012, c. 80, § 2, eff. Nov. 1, 2012; Laws 2013, c. 181, § 1, eff. Nov. 1, 2013; Laws 2014, c. 154, § 2, eff. Nov. 1, 2014; Laws 2015, c. 305, § 3; Laws 2017, c. 390, § 2, emerg. eff. June 6, 2017; Laws 2018, c. 134, § 1, eff. Nov. 1, 2018; Laws 2019, c. 207, § 1, eff. Nov. 1, 2019; Laws 2021, c. 222, § 2, eff. Nov. 1, 2021; Laws 2022, c. 70, § 1, eff. Nov. 1, 2022.
Structure Oklahoma Statutes
Title 63. Public Health and Safety
§63-1-102. Definitions of terms used in Code.
§63-1-103. State Board of Health created.
§63-1-103a. Short title - Oklahoma Public Health Advisory Council Modernization Act.
§63-1-103a.1. Public Health Advisory Councils.
§63-1-104. State Commissioner of Health – Powers and duties.
§63-1-105. State Department of Health created.
§63-1-105a. Liability insurance for certain employees.
§63-1-105b. Soliciting residents for nursing care facilities.
§63-1-105c. Conflicts of interest.
§63-1-105d. Tobacco Prevention and Cessation Revolving Fund.
§63-1-105e. Duties of Department of Health.
§63-1-105f. Office of Accountability Systems.
§63-1-106. State Commissioner of Health - Qualifications - Powers and duties.
§63-1-106.1. Fee schedule for licenses, permits and other health services.
§63-1-106.2. Uniform application to be used in credentialing process.
§63-1-106.3. Oklahoma Food Service Advisory Council
§63-1-106.4. Chief Medical Officer.
§63-1-107. Public Health Special Fund.
§63-1-107.1A. Eldercare Revolving Fund.
§63-1-107.2. Vaccine Revolving Fund.
§63-1-107.3. Health Department Media Campaign Revolving Fund.
§63-1-107.4. Oklahoma Department of Health Civil Monetary Penalty Revolving Fund.
§63-1-108. Federal funds - Grants and donations.
§63-1-109. Right to choose practitioner.
§63-1-110.1. Children First Fund.
§63-1-114.1. Comprehensive Childhood Lead Poisoning Prevention Program.
§63-1-114.2. Dental Health Service.
§63-1-117. Legislative findings - Intent.
§63-1-118. Division of Health Care Information - Powers and duties.
§63-1-119. Collection of health care data.
§63-1-120. Confidentiality of data - Disclosure upon court order - Immunity from liability.
§63-1-132.1. Office of the State Coordinator for Health Information Exchange.
§63-1-201. County board of health - Membership.
§63-1-202. County board of health - Powers and duties.
§63-1-203. County superintendent of health - Appointment - Compensation.
§63-1-204. County superintendent of health - Powers and Duties.
§63-1-206. Functions of health departments.
§63-1-206.1. Nonphysician services - Fees - Agreements to provide services - Disposition of funds.
§63-1-207. Cooperative departments of health - Agreements for.
§63-1-208. Funds for operation of health departments.
§63-1-208.1. Regional guidance centers and services.
§63-1-209. Cities and towns - Health authorities - Licensing and Inspection - Ordinances.
§63-1-210. City-county board of health in certain counties - Membership.
§63-1-211. Organization - Meetings - Compensation.
§63-1-212. Powers and duties of city - county board of health.
§63-1-212.1. Peace officer certificates for certain employees.
§63-1-213. Board of county commissioners - Rules and regulations - Fees.
§63-1-215. Duties of director of city-county health department.
§63-1-216. Agreements with other municipalities, agencies and organizations.
§63-1-217. Fees - Disposition.
§63-1-218.1. Travel expenses - Reimbursement - Payment by credit card.
§63-1-222.1. Governing boards - Membership - Tenure.
§63-1-222.2. Duties of governing boards.
§63-1-222.3. Support of programs.
§63-1-222.4. Screening of minors to avoid duplication of services.
§63-1-223. Constitutional levy for health department.
§63-1-224. Election on constitutional levy.
§63-1-225. Repeal of constitutional levy.
§63-1-226. Annual budget for health department.
§63-1-227. Short title - Intent of Legislature - Office of Child Abuse Prevention created.
§63-1-227.2. Power and duties of Office of Child Abuse Prevention.
§63-1-227.3. Comprehensive state plan for prevention of child abuse and neglect.
§63-1-227.6. Funding of child abuse prevention programs.
§63-1-227.7. Director of Office of Child Abuse Prevention - Power and duties.
§63-1-227.8. Child Abuse Prevention Fund.
§63-1-227.9. Child Abuse Training and Coordination Council.
§63-1-229.3. Tobacco Use Reduction Fund.
§63-1-229.7. Retention of unexpended appropriated funds.
§63-1-229.8. Contractor reports – Report to Governor and Legislature.
§63-1-229.11. Short title - Prevention of Youth Access to Tobacco Act.
§63-1-229.15. Signs in retail establishments required – Fines.
§63-1-229.16. Notice to retail employees - Signed acknowledgement.
§63-1-229.17. Vending machine sales restricted.
§63-1-229.20. Regulation by agencies or political subdivisions restricted.
§63-1-229.22. Enforcement of Act by ABLE Commission.
§63-1-229.23. Municipalities to furnish information to ABLE Commission.
§63-1-229.24. Distribution of administrative fines to municipalities.
§63-1-229.25. Certain other penalties authorized by law not excluded.
§63-1-229.29. Retail sale of alcoholic beverages or low-point beer – Posting of signs – Penalty.
§63-1-229.31. Enforcement of act - Enlistment of persons under 21 years of age.
§63-1-229.32. Other penalties authorized by law not excluded.
§63-1-229.33. Prevention of Youth Access to Alcohol Revolving Fund.
§63-1-229.34. Hired bus or limousine service.
§63-1-229.35. Vapor manufacturers to attest to applying for or receiving a marketing order.
§63-1-231. Short title - Purpose.
§63-1-232. Statewide program to promote health care.
§63-1-233. Providers as state employees - Protection from liability - Employment contracts.
§63-1-233.1. Short title - Ava's Law – Information to be provided to pregnant individuals.
§63-1-234.1. Breast-feeding – Declaration as right.
§63-1-237.1. Postponing Sexual Involvement for Young Teens program.
§63-1-242. Short title - Maternal Mortality Review Act.
§63-1-242.2. Maternal Mortality Review Committee.
§63-1-242.3. Investigation – Subpoena for production of records.
§63-1-242.4. Composition and structure of Committee.
§63-1-243. Requirements concerning perinatal mental health disorders.
§63-1-260.2. Purposes of act – Duties of Board of Health and Department of Health.
§63-1-260.4. Osteoporosis prevention and awareness.
§63-1-270. Plan for statewide coordinated system of care for stroke.
§63-1-270.2. Human embryo – Stem cell research – Reporting system.
§63-1-280.1. Sooner Start program treatment of autism spectrum disorders - Funding - Contracts.
§63-1-280.3. Outreach program providing intensive behavioral intervention for children with autism.
§63-1-290.2. Registered nurses - Physician-approved protocols.
§63-1-290.3. Construction of act - Severability.
§63-1-291.1. Short title-Oklahoma Veterans Brain Injury Treatment and Recovery Act of 2014.
§63-1-291.2. Hyperbaric oxygen treatment defined.
§63-1-291.3. Veterans Traumatic Brain Injury Treatment and Recovery Revolving Fund.
§63-1-291.6. Payment of treatment costs.
§63-1-302. Rules and regulations.
§63-1-303. System of vital statistics.
§63-1-304. State Commissioner of Health - Duties.
§63-1-311. See the following versions:
§63-1-311.1. Obtaining social security numbers for live births and deaths.
§63-1-311v1. Birth certificates - Filing - Contents - Surrogates.
§63-1-311v2. Birth certificates - Filing - Contents - Surrogates.
§63-1-312. Infant of unknown parentage.
§63-1-313. Delayed birth certificate.
§63-1-314. Delayed death certificate.
§63-1-315. Judicial proceeding for record of birth.
§63-1-316. New certificate of birth.
§63-1-316a. Heirloom birth certificates.
§63-1-316b. Short title - Death Certificate Accuracy Act.
§63-1-317. See the following versions:
§63-1-317a. Electronic capture of death certificate.
§63-1-317b. List of all registered deaths of residents indicated as veterans on death record.
§63-1-317c. Confidentiality and disclosure – Construction with Section 1-323.
§63-1-317d. Sudden unexplained infant death investigation (SUIDI).
§63-1-317v1. Death certificate - Filing - Contents.
§63-1-317v2. Death certificate - Filing - Contents.
§63-1-318. Fetal death certificate - Filing - Contents.
§63-1-318.1. MISSing Angels Act – Christopher and Kendall’s Law.
§63-1-318.2. Certificate of birth for stillborn child.
§63-1-319. Disinterment Permit - Notice of Disinterment and Reinterment.
§63-1-320. Extension of time to file certificate.
§63-1-321. Amendment of certificate or record.
§63-1-322. Copies of records - Certification.
§63-1-323. Vital statistics records confidential – Exceptions – Online public index.
§63-1-323.1. Notification system for identifying missing children.
§63-1-324. Certified copies of records - Evidentiary value.
§63-1-324.1. Birth, death or stillbirth certificates - Prohibited acts - Penalties.
§63-1-324.2. Unlawful acts - Penalties.
§63-1-325. Fees for certified copies of records - Noncollectible drafts - Enlistees.
§63-1-326. Inmates of institutions - Records - Deaths.
§63-1-327. Information concerning birth or death.
§63-1-329.1. Cremation - Burial at sea - Bodies for pathologic study - Disposal permits.
§63-1-334. Marriage and divorce – Nonidentifiable aggregate data.
§63-1-402. Examinations for tuberculosis.
§63-1-403. Exposure to tuberculosis.
§63-1-405. Freedom to choose treatment.
§63-1-409. Reciprocal agreements.
§63-1-410. Hospitalization and treatment.
§63-1-450. Oklahoma Plan for Comprehensive Treatment of Chronic Obstructive Pulmonary Disease Act.
§63-1-502. Rules and regulations.
§63-1-502.1. Communicable diseases - Universal precautions - Rules and regulations - Risk exposure.
§63-1-502.4. Notice to funeral director or embalmer of communicable disease.
§63-1-503. Reports of disease.
§63-1-504. Quarantine - Violation of quarantine unlawful - Injunctive relief.
§63-1-505. Removal of diseased persons authorized.
§63-1-506. Permission for removal of diseased persons.
§63-1-507. Schools - Attendance of diseased pupils.
§63-1-508. Animals - Quarantine.
§63-1-509. Inflammation of eyes of newborn infants.
§63-1-510. Required eye treatment of infant - Exemption.
§63-1-515. Pregnant women - Tests for syphilis.
§63-1-515.1. Physicians attending upon pregnant females – Blood sample.
§63-1-516. Reports - Blood tests for syphilis.
§63-1-518. Report and treatment of disease.
§63-1-520. False discharge from treatment - Penalty.
§63-1-521. Treatment by person not a physician.
§63-1-522. Treatment without prescription.
§63-1-526. Rules and regulations.
§63-1-527. Reports of a sexually transmitted infection.
§63-1-528. Sexually transmitted infection cases - Instructions - Notification.
§63-1-529. Investigations by health officers.
§63-1-530. Protection against spread of infection.
§63-1-531. Certificates of freedom from infection.
§63-1-532. Publicity of information and reports.
§63-1-532.1. Minor's consent to examination and treatment for sexually transmitted infections.
§63-1-533. See the following versions:
§63-1-534.2. State Plan for the Prevention and Treatment of AIDS - Contents.
§63-1-539.1. Short title - Definitions.
§63-1-539.2. Needlestick Injury Prevention Committee – Appointments – Powers and duties.
§63-1-539.3. Uniform rules to be promulgated by certain state agencies.
§63-1-540. Information campaign on DES.
§63-1-541. Registry of persons who took DES.
§63-1-542. Report of findings and recommendations.
§63-1-543. Short title - Screening for detection of congenital or acquired hearing loss.
§63-1-543.3. Grand funding for sickle cell disease.
§63-1-545. Publication of results - Release of information.
§63-1-546.1. Short title – Legislative findings.
§63-1-546.5. District attorney multidisciplinary teams - Appropriate dispositions.
§63-1-550.2. Birth defects surveillance program.
§63-1-550.3. Record of Infants Born Exposed to Alcohol and Other Harmful Substances.
§63-1-550.4. Short title – Fayelen's Law.
§63-1-550.5. Birthing facility – Pulse oximetry screening.
§63-1-552. Investigations and other actions - Compilation and evaluation of information.
§63-1-553. Bone marrow donation program.
§63-1-553.1. Mammography reports – Breast density classification.
§63-1-554. Oklahoma Breast and Cervical Cancer Act.
§63-1-556. Contract review and recommendation.
§63-1-557. Breast and Cervical Cancer Act Revolving Fund.
§63-1-558. State income tax return check-off.
§63-1-559. Belle Maxine Hilliard Breast and Cervical Cancer Treatment Revolving Fund.
§63-1-559.2b. Legislative findings.
§63-1-559.2c. Obesity reduction programs - Department duties - Rules.
§63-1-563. Genetic counselors - License required.
§63-1-564. Requirements for licensure - Issuance of temporary license.
§63-1-565. Requirements for temporary licensure - Term of license.
§63-1-566. Exceptions to licensure requirement.
§63-1-567. Continuing education requirements.
§63-1-569. Licensure requirements - Rules.
§63-1-570. Genetic Counseling Licensure Revolving Fund.
§63-1-575. Short title - Courtney's Law – Information for chromosomal disorders.
§63-1-604. Transfer of General Hospital to City of Clinton.
§63-1-605. Unexpended appropriations - Continuance.
§63-1-702. Licenses required - Practice of healing arts or medicine
§63-1-702c. Enhanced reimbursement program for services provided to Medicare beneficiaries.
§63-1-702e. Uncompensated Care Equalization Revolving Fund.
§63-1-703. Licenses - Application - Evidence of qualifications.
§63-1-704. Licenses - Fees - Duration - Posting.
§63-1-706. Licenses - Issuance, suspension and revocation.
§63-1-706.11. Recognition of Center as resource to state's emergency medical services system.
§63-1-706.12. Purposes of Center.
§63-1-706a. Short title - No Patient Left Alone Act.
§63-1-707. Rules and standards – Oklahoma Hospital Advisory Council.
§63-1-707a. Staff privileges - Applications - Psychologists.
§63-1-707b. Granting of staff privileges - Criteria.
§63-1-709. Information confidential.
§63-1-711. Survey and inventory of hospitals and health centers.
§63-1-713. Standards of United States Surgeon General to be followed - Reports.
§63-1-719. Bonds of counties, cities and towns.
§63-1-722. Electronic- or computer-generated signatures of physician.
§63-1-723. Primary Health Care Development Revolving Fund.
§63-1-723.2. Discount program for qualified self-pay patients - Defense in collection action.
§63-1-724. Health centers – Contracts, donations, and grants.
§63-1-725.1. Short title - Transparency in Health Care Prices Act.
§63-1-725.3. Publicly available prices for common services.
§63-1-725.4. Prices required for certain services.